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Background: Schizophrenia can be conceptualized as a form of dysconnectivity
between brain regions. To investigate the neurobiological foundation of dysconnectivity,
one approach is to analyze white matter structures, such as the pathology of fiber
tracks. S100B is considered a marker protein for glial cells, in particular oligodendrocytes
and astroglia, that passes the blood brain barrier and is detectable in peripheral blood.
Earlier Studies have consistently reported increased S100B levels in schizophrenia. In
this study, we aim to investigate associations between S100B and structural white matter
abnormalities.
Methods: We analyzed data of 17 unmedicated schizophrenic patients (first and
recurrent episode) and 22 controls. We used voxel based morphometry (VBM) to detect
group differences of white matter structures as obtained from T1-weighted MR-images
and considered S100B serum levels as a regressor in an age-corrected interaction
analysis.
Results: S100B was increased in both patient subgroups. Using VBM, we
found clusters indicating significant differences of the association between S100B
concentration and white matter. Involved anatomical structures are the posterior
cingulate bundle and temporal white matter structures assigned to the superior
longitudinal fasciculus.
Conclusions: S100B-associated alterations of white matter are shown to be existent
already at time of first manifestation of psychosis and are distinct from findings in recurrent
episode patients. This suggests involvement of S100B in an ongoing and dynamic
process associated with structural brain changes in schizophrenia. However, it remains
elusive whether increased S100B serum concentrations in psychotic patients represent
a protective response to a continuous pathogenic process or if elevated S100B levels
are actively involved in promoting structural brain damage.
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INTRODUCTION
Structural abnormalities in the brains of schizophrenic patients
have been frequently reported using post mortem (Harrison,
1999) and in vivomagnetic resonance imaging (MRI) techniques
(Pearlson and Marsh, 1999; Wright et al., 2000; Gupta et al.,
2015). Schizophrenia has been shown to be associated with
ventricular enlargement and slightly decreased overall brain
volume. Regional volume abnormalities were mainly localized
in limbic structures and the temporal lobe (Bogerts et al.,
1990; Wright et al., 2000). Neuroanatomical findings include
decreased presynaptic and dendritic markers consistent with
reduced neuron size and increased neuron density (Pakkenberg,
1993; Harrison, 1999). These findings and results from
neuropsychological and neuroimaging studies of function have
led to the notion of a disturbance of connectivity between brain
regions (Andreasen et al., 1998; Lipska and Weinberger, 2002).
Consequently, abnormalities in interconnecting white
matter (WM) structures have attracted interest (Davis et al.,
2003). While investigations of global white matter volume
have been inconclusive, local changes in white matter have
been demonstrated in prefrontal cortex, temporo-parietal and
parieto-occipital regions, splenium, cingulum, and posterior
capsule, supporting the hypothesis of abnormal connectivity
in schizophrenia (Davis et al., 2003; Kubicki et al., 2007;
Ellison-Wright et al., 2008). However, the pathophysiological
processes underlying structural abnormalities, their time
dimension, and the relation to symptomatology and outcome
are still to a large extent ambiguous. Structural abnormalities
of the brain parenchyma like white matter myelin disturbance,
deterioration of the neuropil, loss of synaptic connectivity, and
functional impairment of oligodendrocytes have been proposed
to contribute to the etiology of schizophrenia (Selemon and
Goldman-Rakic, 1999; Davis et al., 2003; Katsel et al., 2011;
Streitbuerger et al., 2012; Hercher et al., 2014).
S100B is a small acidic Ca2+-binding protein that is found in
high abundance within the central nervous system (CNS). It is
secreted by astrocytes and oligodendrocytes, and is also expressed
in ependyma and neurons (Donato, 2001; Eldik andWainwright,
2003; Schroeter et al., 2013). A post mortem histological study
in human brain tissue showed that S100B immunostained cells
in cortical regions have astrocytic morphology while most
S100B positive cells located in white matter regions resembled
oligodendrocytes (Steiner et al., 2007).
As a rather small protein with a molecular weight of 21kDa
in its biologically active homodimeric form, S100B passes the
blood brain barrier, and thus is detectable as a brain derived
protein in peripheral blood (Reiber, 2001). Measurements of
S100B in serum have been proven to valuably reflect the
S100B concentration in cerebrospinal fluid (CSF) in healthy
individuals as well as in patients with various neurological
diseases (Reiber, 2001). In schizophrenic patients, increased
S100B serum concentration is a repeatedly reported finding
(Aleksovska et al., 2014).
Though many effects of S100B have been explored,
the pathophysiologic role of elevated S100B levels in
schizophrenia is not yet clarified. S100B is implicated in a
number of Ca2+-dependent regulation processes, including
phosphorylation, enzyme activity, cell metabolism, and
signaling pathways (Donato, 2001; Rothermundt et al., 2004a).
Extracellular effects of S100B depend on its local concentration.
While nanomolar concentrations have been demonstrated to be
neuroprotective and neurotrophic, micromolar concentrations
have been shown to have neurotoxic effects and to induce
apoptosis (Eldik and Wainwright, 2003; Gonçalves et al., 2008).
Hence, S100B elevation can be considered to be a secondary
attempt to protect nervous tissue, e.g., against glutamate
induced stress (Ahlemeyer et al., 2000). Contrariwise, pathologic
overproduction of S100B could also induce neuroinflammatory
responses and thus make S100B a brain damaging agent itself
(Eldik and Wainwright, 2003).
This study aims to ascertain whether there are associations
between S100B elevation as a possible marker for glial function
or dysfunction and local structural white matter changes in
brains of schizophrenic patients. We utilized a voxel based
morphometry (VBM) approach, since it is an established
automated and thereby user-independent method well suited to
detect local structural differences in the whole brain without
prior definition of regions of interest by analysing in vivo
magnetic resonance images (MRI; Ashburner and Friston, 2000;
Honea et al., 2005). Building on prior knowledge from previous
neuroimaging studies, interaction analyses, and histological post
mortem studies, we hypothesized that an interaction between
S100B andWM can be found in interconnecting fronto-temporal
white matter structures (Steiner et al., 2008; Streitbuerger et al.,
2012; Schroeter et al., 2013) and other repeatedly reported white
matter structures within the frontal and temporal lobe as well as
in cingulum bundle and corpus callosum (White et al., 2008).
METHODS
Subjects
We investigated 17 consecutively admitted patients from the
inpatient unit of the Department of Psychiatry of the Jena
University Hospital fulfilling DSM IV criteria for schizophrenia
(all Caucasians, epidemiologic data in Table 1). Eleven patients
suffered their first acute psychotic episode (FEP), of which 8 were
drug-naïve and 3 free of neuroleptic medication for at least 5
days. Six patients had been psychotic for more than one time,
thus suffering from a recurrent acute psychotic episode (REP).
Of those, 2 patients were still naïve in terms of neuroleptic
drugs; 4 were free of neuroleptic medication for at least 4
days. Diagnosis was made for each patient by two independent
board-certified psychiatrists (St. S., H. S.) and confirmed by
structured clinical interview. Patients were compared to 22
healthy volunteers (all Caucasian, epidemiological data given in
Table 1). None of the healthy controls had a personal or family
history of psychiatric disorder. Subjects with any acute or chronic
inflammatory disease or recent treatment with non-steroidal or
steroidal anti-inflammatory drugs were excluded from the study.
For all subjects, blood samples were taken for S100B serum
level analysis and high-resolutionMRI was performed. The study
was approved by the Research Ethics Committee of the Jena
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TABLE 1 | Epidemiological data and status of medication for each group.
Control Group First episode
patients
Recurrent episode
patients
Number (N) 22 11 6
Gender (male/female) 9/13 5/6 1/5
Age (years ± SD) 34.73 (±10.30) 30.53 (±9.95) 42.00 (±9.28)
Drug-naïve (number) 8 2
Drug-free (number,
duration of drug-free
period)
3 (5–14 days) 4 (4 days–5 months)
Previous medication Risperidone Risperidone,
Olanzapine,
Haloperidole
University Hospital. All subjects gave written informed consent
to participate in the study.
Acquiring and Storage of Blood Samples
Venous blood (10ml) was taken from an antecubital vein using
a 19-gauge butterfly attached to a dry plastic syringe. Blood
was allowed to clot for 30min at room temperature. Serum was
separated by centrifugation (10min at 3000 rpm) within 2 h after
collection and stored in 1ml aliquots at−72◦C.Mean duration of
storage was 28.6 days (range: 12–56 days, SD: ±10.0 days). After
thawing, sera were re-centrifuged and stirred carefully in order to
avoid any inhomogeneities of the specimen.
Analysis of S100B Protein Levels
S100B concentrations were determined by applying the LIAISON
Sangtec 100 assay (AB Sangtec Medical, Bromma, Sweden), a
quantitative automated luminometric immunoassay, according
to the manufacturer’s instructions. The assay’s lower detection
limit for S100B is 0.02 µgl−1. The intra-assay (within-run)
imprecision (CVs) is between 2.6 and 6.4 %, depending on
concentration. The inter-assay variation (CVs) is between 2.2 and
10.7 %. Analytical recovery ranges between 91 and 100.
Acquisition of Structural Data and Image
Processing
High-resolution MRI was performed on a 1.5 T Philips
Gyroscan ACSII system. We acquired 256 sagittal slices using
a T1-weighted sequence (TR = 13ms, TE = 5ms, flip
angle 25◦) with isotropic voxel size of 1 × 1 × 1mm3.
Data preprocessing and analysis was performed using SPM2
software (Statistical Parametric Mapping; Wellcome Department
of Cognitive Neurology, London, UK).
For morphometric analysis of the data we used voxel-based
morphometry (VBM). VBM is a fully automatic technique to
computationally analyze of differences in local gray or white
matter volume. This method involves the following steps: (i)
spatial normalization of all images to a standardized anatomical
space by removing differences in overall size, position, and
global shape; (ii) extraction of gray and white matter from the
normalized images; and (iii) analysis of differences in local gray
and white matter volume across the whole brain (Ashburner
and Friston, 2000). We applied an optimized method of VBM
(Ashburner and Friston, 2000; Good et al., 2001) using the
VBM2 Toolbox (http://dbm.neuro.uni-jena.de/vbm). The spatial
normalization to the standard anatomical space was performed
in a two-stage process. In the first step, we registered each image
to the International Consortium for Brain Mapping (ICBM)
template (Montreal Neurological Institute, Montreal, Canada),
which approximates Talairach space. The normalized images
of all subjects were averaged and smoothed with a 8mm full-
width at half-maximum (FWHM) Gaussian kernel; this averaged
image was then used as a new template to reduce scanner-
and population-specific bias. In the second normalization step,
we locally deformed each image of our entire group to the
new template using a non-linear spatial transformation. This
accounts for the remaining shape differences between the images
and the template and improves the overlap of corresponding
anatomical structures. Finally, normalized images were corrected
for non-uniformities in signal intensity and partitioned into gray
and white matter, cerebrospinal fluid, and background using a
modified mixture model cluster analysis. The resulting maps
represent the local probability of belonging to a particular tissue
type via voxel-wise values between 0 and 1. Because we applied
spatial registration the same voxel location in each image should
approximately correspond to the same brain structure. Using the
probability values, we examined the relative concentration of one
tissue type [i.e., the proportion of gray matter (GM) to other
tissue types within a region]. We restricted the statistical analysis
to areas with aminimum probability value of 0.1 to avoid possible
edge effects around tissue borders. To remove unconnected non-
brain voxels (e.g., rims between brain surface and meninges),
we applied a series of morphological erosions and dilations
to the segmented images (Good et al., 2001). Because these
segmentations are often affected by noise we introduced spatial
constraints based on neighboring voxels by using a Markov
Random Field Model (Cuadra et al., 2005). The resulting white
matter images were smoothed with a 12mm FWHM Gaussian
kernel.
Statistical Analysis
Statistical analysis of S100B serum levels was performed using
the software package SPSS 15 for Windows. For evaluation of
group differences, univariate analysis of variance (ANOVA) was
performed using S100B concentration as the dependent variable,
GROUP as a between-subject factor, and GENDER and AGE as
covariates. To further investigate group differences found to be
significant in ANOVA, we performed multiple pairwise group
comparisons using a two-tailed Student’s t-test with significance
defined as p < 0.05 (corresponding to p < 0.0167 Bonferroni
adjusted alpha).
Groupwise comparison of white matter imaging data was
performed using a general linear model implemented in the
software package SPM2. To account for variance related to age
effects (due to different mean age between the patient groups),
we included age as a confounding variable into the model. For
resulting statistics, we set the significance threshold at p <
0.001. Only clusters exceeding the expected number of voxels per
cluster (according to the Gaussian Random Field theory) were
considered.
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Assessment of associations between S100B concentration and
structural abnormalities was realized using a general linear model
in SPM2 with S100B concentration defined as a regressor. To
account for age-related effects, we included age as confounding
variable into the model. For pairwise group comparison, this
type of analysis equals an interaction model (Smesny et al.,
2010) testing for different regression slopes of white matter
density related to S100B concentration between the groups in
each voxel (S100B concentration vs. group interaction). Because
variance was expected to differ between samples, we applied
a non-sphericity correction. Again, all statistical images were
thresholded at p< 0.001 and only clusters exceeding the expected
number of voxels per cluster were reported. To support the
anatomical labeling of our findings, we used the Mori MRI Atlas
of HumanWhite Matter (Mori et al., 2005).
RESULTS
Sample Characteristics and S100B Serum
Concentration
There was a difference in mean age between groups (Table 1).
Group differences in mean age at the time of investigation
originate from the natural age of onset and the course of the
disease, leading to a consistently higher age in recurrent-episode
patients (t-test: for FEP vs. REP: p = 0.001, for C vs. REP:
p = 0.006, for C vs. FEP: p = 0.271). We took this into account
by considering age as a covariate in all following analyses, thus
assuring our findings are not due to effects of age. In terms of
gender distribution, Fisher’s exact test (gender by group) yielded
p = 0.280 for C vs. FEP, p = 0.059 for C vs. REP, and p = 0.055
for FEP vs. REP, indicating that the gender distribution was not
statistically significant. Also, univariate ANOVA and correlation
analysis did not reveal any significant effect of GENDER or AGE
on S100B serum concentration. Univariate ANOVA resulted in
significant effects of GROUP on S100B levels (F = 6.310, p <
0.005; AGE and GENDER corrected model: F = 4.011, p =
0.009). The t-test results were congruent with previous findings
that reported significantly higher S100B serum concentrations in
both patient groups compared to controls (C vs. FEP: p = 0.006,
C vs. REP: p = 0.008). No significant group differences were
found between first and recurrent episode patients. Results and
statistical information of S100B serum concentration analysis
are presented in Table 2. A graphical presentation of the data is
shown in Figure 1.
TABLE 2 | Results and corresponding statistical information of S100B
serum concentration analysis, specified in µg/ml.
Control Group First episode
patients
Recurrent
episode patients
Range 0.01−0.10 0.03−0.13 0.05−0.12
Mean ± SD 0.057 ± 0.023 0.084 ± 0.028 0.089 ± 0.026
Median 0.06 0.08 0.09
95% confidence
interval
0.047−0.067 0.065−0.103 0.061−0.116
VBM-Based Pairwise Group Comparison of
Brain Imaging Data
By performing a VBM-Based group comparison of MRI data, we
found local white matter structural differences between patients
and controls as well as between both patient groups. A detailed
listing of the results of this analysis is presented in Table 3.
When comparing healthy controls with patients suffering
from their first psychotic episode (C vs. FEP), structural
differences in white matter were located in the right medial
orbital gyrus of the frontal lobe (diminished white matter in
patients) and in white matter of the parietal lobe corresponding
to the posterior cingulum bundle (increased white matter in
patients). The VBM-based comparison of white matter between
healthy controls and patients suffering from a recurrent psychotic
episode (C vs. REP) yielded more and larger clusters denoting
differences between these groups than between controls and
first episode patients. The largest cluster indicating diminished
white matter in recurrent episode patients was located in the
medial area of the occipital lobe and was assigned to the
inferior fronto-occipital fasciculus. Others were located in the
cuneus, left frontal lobe, and frontal white matter assigned to
the corticothalamic tract. Increased white matter in recurrent
episode patients was found in the right superior temporal gyrus
assigned to the inferior longitudinal fasciculus, and in the left
cerebellum.
There were clusters indicating diminished white matter in first
episode patients as compared to recurrent episode patients (FEP
vs. REP). These were located in the left and right pontine area
assigned to the corticospinal tract, the left occipital lobe, the left
parahippocampal area, and the right frontal lobe.
FIGURE 1 | SPSS generated boxplot for results of S100B serum
concentration analysis. Black bar within box: median, gray box: 25–75%
quartiles; small black bars: minimum to maximum; circles: outliners. Significant
group differences are marked with **p < 0.01.
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TABLE 3 | Results of group comparison of white matter brain structure between controls and patient groups (VBM-based analysis).
Group comparison Cluster size T-value (voxel) Anatomical region Assigned white matter structure
C > FEP 251 4.25 Frontal lobe, medial orbital gyrus R
C < FEP 209 4.37 Parietal lobe, region of gyrus Andrei Retzii L Subcallosal white matter, Posterior cingulum bundle
C > REP 3606* 7.08 Occipital lobe, median area L Inferior fronto-occipital fasciculus
615 4.77 Cuneus L/R
194 4.03 Frontal lateral white matter compartment R Corona radiata, Corticothalamic tract
519 3.49 Frontal lobe, F1 region L
C < REP 299 4.00 Temporal lobe, superior temporal gyrus,
Angular gyrus R
Inferior longitudinal fasciculus, Arcuate fasciculus
711 3.97 Cerebellum L
FEP > REP 1033 5.40 Occiptal lobe, median and basal parts L Inferior fronto-occipital fasciculus
2064 4.82 Middle and upper pontine area, lateral
circumference, cerebellar peduncle L
Corticospinal tract
209 4.57 Parahippocampal area T4/T5 L Fornix
519 4.04 Middle and upper pontine area, lateral
circumference, cerebellar peduncle R
Corticospinal tract
265 3.78 Frontal lobe, F1 region, middle part R
FEP < REP n.s. n.s. n.s. n.s.
Between-group differences in white matter structure were found in reported clusters. Only clusters showing group differences at a significance level of p < 0.001 and exceeding the
expected number of voxels per cluster according to the Gaussian Random Field theory are reported. *p < 0.001 (cluster-level, FWE corrected for multiple comparisons). Anatomic
labeling, corresponding cluster size and T-value are shown for each cluster. The type of group comparison is indicated in the form A < / > B, where A > B indicates lower white matter
in group B compared to A and vice versa. Lateralization is marked with L for left and R for right hemisphere. Anatomical names of white matter structures were assigned using Mori: MRI
Atlas of Human White Matter (Mori et al., 2005). C, control; FEP, first episode patients; REP, recurrent episode patients. C, control; FEP, first episode patients; REP, recurrent episode
patients.
Associations of S100B Serum Levels and
White Matter Structure in Healthy Controls
We did not find statistically significant associations between
S100B serum concentration and white matter brain structure in
healthy controls.
VBM-Based Pairwise Group Comparison of
Associations between S100B Serum Levels
and White Matter Brain Structure
We found differences in the association between local white
matter structures and S100B concentration (denoted as
interaction in the following text) between patients and controls
as well as between both patient groups. A detailed listing of
the results of this VBM-Based interaction analysis is presented
in Table 4. Figures 2–4 show localization and dimensions of
each significant cluster listed in Table 4 as an overlay onto the
averaged T1-image of all subjects in axial and sagittal plane. Also
shown are scatter plots and corresponding regression lines of
S100B concentration vs. white matter values obtained from the
1st eigenvariate of the corresponding cluster.
Differences in the association between S100B and white
matter between healthy controls and first episode patients (C
vs. FEP) could be found in the left and right superior temporal
gyrus assigned to the inferior longitudinal fasciculus (negative
association in patients, illustrated in Figure 2: clusters 1, 2, and
3) and in the right postcentral dorsal white matter compartment
assigned to the posterior cingulum bundle (steeper regression
gradient in patients, Figure 2: cluster 4). In both cases, local white
matter was diminished in patients.
In recurrent episode patients, there was a similar finding in
the right postcentral white matter (posterior cingulum bundle,
Figure 3: cluster 6). Also, there was a finding located in the
superior temporal gyrus of the left temporal lobe (Figure 3:
cluster 6), but the association between S100B and white matter
was positive in recurrent episode patients and negative in first
episode patients.
This type of interaction (negative association between S100B
and white matter in first episode patients, positive association
in recurrent episode patients) was also found in the direct
comparison of both patient groups. With the chosen level of
significance, a cluster in the right superior temporal gyrus could
be identified (Figure 3: cluster 7). Additionally, a larger cluster
(Figure 3: cluster 9, cluster-size 1289) could be detected in
the right fronto-parietal white matter compartment, and was
assigned to the superior longitudinal fasciculus. Other findings
were located in the right temporal lobe and left postcentral
region.
VBM-Based Pairwise Group Comparison
between S100B and Gray Matter
We followed a hypothesis driven approach and considered S100B
as a protein associated with white matter (Schroeter et al., 2013).
However, to complete the picture, we additionally calculated
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TABLE 4 | Results of pairwise group comparison of associations between S100B concentrations and white matter brain structure (VBM-based interaction
analysis).
Interaction Cluster Number Cluster Size T-Value (voxel) Anatomical region Assigned white matter structure
C > FEP 1 175 3.80 Temporal lobe, superior temporal gyrus L Inferior longitudinal fasciculus
Arcuate fasciculus
2 880 5.13 Temporal lobe, superior temporal gyrus R Inferior longitudinal fasciculus
Arcuate fasciculus
3 400 4.17 Dorsal parietal white matter compartment
Postcentral region R
Superior longitudinal fasciculus
C < FEP 4 1214 5.55 Parietal white matter compartment
Postcentral region R
Posterior cingulum bundle
C > REP n.s. n.s. n.s. n.s.
C < REP 5 818 4.28 Temporal lobe, superior temporal gyrus
Angular gyrus L
Superior longitudinal fasciculus
Arcuate fasciculus
6 617 4.58 Parietal white matter compartment
Postcentral region R
Posterior cingulum bundle
FEP > REP n.s. n.s. n.s. n.s.
FEP < REP 7 416 4.19 Temporal lobe, superior temporal gyrus,
Insula R
Inferior longitudinal fasciculus
8 945 5.32 Temporal lobe, T1/T2 region Arcuate fasciculus
9 1289 4.84 Fronto-parietal white matter compartment R Superior longitudinal fasciculus
10 220 4.06 Parietal lobe, Postcentral region
Abbreviations, labeling and data structure as in Table 3. Interaction type is indicated in the form A < / > B, whereby A > B indicates a significantly steeper gradient of regression
(association between S100B and white matter) of A as compared to B and vice versa. Clusters are numbered for easier identification in figures and discussion. C, control; FEP, first
episode patients; REP, recurrent episode patients.
results for gray matter in the same way as we did for white
matter. It resulted in only 2 small clusters in the bordering
region between gray and white matter—one next to the posterior
cingulum bundle and one in the temporal lobe approximately
corresponding to the neighborhood of the localization of cluster
2 in the white matter analysis but with much smaller extent (data
not shown).
DISCUSSION
This interaction analysis utilized a combined approach of voxel
based brain morphometry and quantitative analysis of S100B
serum concentration. It aimed to identify correlations between
S100B concentration and white matter brain structure changes
for schizophrenic patient groups at different stages of the
disorder as compared to healthy controls. It also intended to
show anatomic localizations of group differences. To minimize
possible confounding effects, we ensured that all patients were
free of antipsychotic medication at the time of investigation.
Recurrent episode patients were significantly older at the time
of investigation than controls and first episode patients. We
took this into account by considering age as a nuisance variable
in all VBM-based analyses and demonstrated that our findings
were not due to age effects. Furthermore, investigation of patient
subgroups (first episode and recurrent episode patients) allowed
us to characterize patterns of S100B-associated structural brain
abnormalities not only at the time of initial schizophrenic
manifestation, but also at a recurrent episode stage.
S100B Serum Concentration
S100B serum concentration was significantly increased in both
patient groups when compared to healthy volunteers (Table 2,
Figure 1), which constitutes a replication of findings in other
first episode and chronic patient populations (Rothermundt et al.,
2004a; Aleksovska et al., 2014). We did not find differences in
S100B serum concentration between first and recurrent episode
patients. When interpreting the latter result, one should bear
in mind that, at the time of investigation, patients of both
groups were unmedicated (or drug naïve) and had suffered an
acute psychotic episode. Based on findings from other studies
demonstrating that S100B decreases only in some patients
when medicated (Rothermundt et al., 2001), or that it stays
elevated even after 24 weeks of treatment in chronic patients
(Rothermundt et al., 2004b), it is reasonable to assume that
S100B elevation in schizophrenic patients is associated with
pathophysiological processes inherent to psychotic episode in
schizophrenia or, more likely, the disorder itself (Rothermundt
et al., 2004a).
VBM-Based Pairwise Group Comparison of
Brain Imaging Data
In this section, we will discuss the results of the pairwise
group comparison of white matter brain imaging data as
presented in Section VBM-Based Pairwise Group Comparison
of Brain Imaging Data and Table 3. While the main goal
of this study was to identify possible interrelations between
structural white matter changes and S100B concentration (see
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FIGURE 2 | VBM-based pairwise group comparison of associations between S100B concentration and white matter brain structure (interaction
analysis): controls (C) vs. first episode patients (FEP). Clusters shown are significant as stated and numbered in Table 4 and are shown as overlay to the T1
average image in axial and sagittal plane for each group comparison as indicated below anatomical images. The T1 averaged image was obtained from images of all
participants of this study. Positive interaction (regression of group A > B) is indicated by red/yellow color, negative interaction (A < B) by blue color (colorbar with
corresponding T-values shown in Figure 3). Numbering of clusters is as according to Table 4. Scatter plots showing S100B concentration against white matter
values (obtained from 1st Eigenvariate of its corresponding cluster) and corresponding regression lines are demonstrated exemplarily for each found interaction
pattern. Color coding in scatter plots: gray, C, controls; red, FEP, first episode patients; blue, REP, recurrent episode patients.
Sections Associations of S100B Serum Levels and White Matter
Structure in Healthy Controls and VBM-based Pairwise Group
Comparison of Correlations between S100B Serum Levels and
White Matter Brain Structure), presentation and discussion of
just the structural findings may be helpful for understanding and
embedding results of the following interaction analysis into a
broader neuroanatomical and pathophysiological context.
First Episode Patients
We found differences in local white matter structures already
present in the brains of first episode patients when compared to
controls, even though most of these patients were drug-naïve.
These differences were located in frontal regions (diminished
WM) and parietal white matter structures (elevated WM)
corresponding to the posterior part of the cingulum bundle.
Only few studies analyzing whole brain white matter structure
in untreated first episode patients have been conducted so
far (Kubicki et al., 2007; Kyriakopoulos and Frangou, 2009;
Samartzis et al., 2014). Reductions of fractional anisotropy (FA)
were found, among other regions, in the right parietal WM
(Kyriakopoulos and Frangou, 2009). A recent DTI-based study
revealed lower FA bilaterally in regions corresponding to the
superior and inferior longitudinal fasciculus, the forceps major,
the thalamic radiation, and the corpus callosum (Pérez-Iglesias
et al., 2010). These and our findings strengthen the notion of
disturbed white matter integrity being present already in very
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FIGURE 3 | VBM-based interaction analysis: control group (C) vs. recurrent episode patients (REP). Presentation as in Figure 2. In this figure also: color bar
(T-values) and color/symbol coding for scatter plots in Figures 2–4: gray, C, controls; red, FEP, first episode patients; blue, REP, recurrent episode patients.
early stages of the disorder (Pantelis et al., 2005; Begré and
Koenig, 2008; Kyriakopoulos and Frangou, 2009).
Recurrent Episode Patients
In recurrent episode patients we found both, areas with
diminished and increased local white matter (when compared
to the control group). The largest cluster (3606 voxels) with
the highest T-score (7.08) showing locally diminished WM was
located in the left occipital lobe in the region corresponding
to the inferior fronto-occipital fasciculus. Another area of
diminished WM was located in the right frontal white matter
corresponding to the corticothalamic tract. These results are in
line with previous VBM-based studies (Suzuki et al., 2002), as
well as DTI-based studies that describe abnormalities of those
structures in terms of decreased FA or reduced track length
(Kubicki et al., 2005; Mitelman et al., 2007; Ellison-Wright and
Bullmore, 2009). Abnormalities of these WM structures provide
evidence supporting the hypothesis of cerebral dysconnectivity in
schizophrenia (Konrad and Winterer, 2008; Ellison-Wright and
Bullmore, 2009).
Increased WM was found in the left cerebellum and the
temporal white matter corresponding to the arcuate fasciculus,
structures that have been repeatedly reported to be altered
in schizophrenia as well (Douaud et al., 2007; Kubicki et al.,
2007; Ellison-Wright and Bullmore, 2009). The possible meaning
and relevance of temporal lobe findings are discussed in more
detail in Section VBM-based Pairwise Group Comparison of
Correlations between S100B Serum Levels andWhite Matter Brain
Structure.
First Episode vs. Recurrent Episode Patients
When comparing the first episode and recurrent episode patient
groups, we found clusters indicating locally diminished white
matter in the REP group but not in the FEP group. Although
this was not a longitudinal study and these results must be
interpreted cautiously, these findings may refer to an ongoing
process of structural remodeling during the disease course. Such a
process has been proposed in several previously published studies
(DeLisi, 1999; Pantelis et al., 2003; Brans et al., 2008; Pol and
Kahn, 2008).
In our sample, we found that the fornix and the inferior
fronto-occipital fasciculus (see Section Recurrent Episode
Patients) differ significantly between the FEP and REP groups.
The fornix is one of the main pathways connecting the
hippocampus with other brain regions and has repeatedly been
shown to be altered in schizophrenia (Kubicki et al., 2005; Kuroki
et al., 2006). It has also been associated with memory impairment
(Nestor et al., 2007). Also, we found that the cerebellar peduncles
and other structures corresponding to the corticospinal tract
differ significantly between the patient groups. Structural changes
of the cerebellar peduncles could contribute to some cognitive
symptoms, since they are part of the frontal-thalamic-cerebellar
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FIGURE 4 | VBM-based interaction analysis: first episode patients (FEP) vs. recurrent episode patients (REP). Presentation as in Figure 2. Color coding in
scatter plots: gray, C, controls; red, FEP, first episode patients; blue, REP, recurrent episode patients.
circuitry that is thought to be disturbed in schizophrenic patients
(Andreasen et al., 1998). The idea of a possible change in these
structures over the course of the disease is supported by results
of some DTI-based studies which reported reduced FA in early
(Kyriakopoulos et al., 2008) and later disease stages (Okugawa
et al., 2006), but not in chronic schizophrenic patients (Wang
et al., 2003).
VBM-based Pairwise Group Comparison of
Correlations between S100B Serum Levels
and White Matter Brain Structure
In the following, we will discuss the results of the VBM-
based interaction analysis (for cluster numbering and anatomical
localization, see Table 4 and Figures 2–4) for all three group
comparisons made (C vs. FEP, C vs. REP, and FEP vs. REP).
This type of analysis was intended to test which local differences
in structural imaging data between groups can be explained by
differences of the chosen regressor S100B.
In first episode patients, S100B-associated differences to
controls were located in the white matter of regions of the left
and right superior temporal gyrus (STG), and in the postcentral
region (clusters 1, 2, and 3). At these localizations, increased
S100B concentrations were associated with diminished local
white matter values (negative correlation). In the right cingulum
bundle (cluster 4), first episode patients showed a positive
correlation between S100B concentrations and white matter
values.
Structural abnormalities of the temporal lobe rank among
the most consistently reported morphometric findings in first
episode patients (Bogerts et al., 1990; Pearlson and Marsh,
1999; Honea et al., 2005). As extensively discussed elsewhere,
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volume differences might follow from changes in neuropil
and white matter (Selemon and Goldman-Rakic, 1999; Davis
et al., 2003; Walterfang et al., 2005). Furthermore, white matter
volume differences involving the inferior longitudinal fasciculus
have been found in a subgroup of schizophrenic patients
(Sigmundsson et al., 2001). Results from studies investigating
white matter fiber tracts with more subtle in vivo methods,
such as diffusion tensor imaging (DTI) or magnetization
transfer imaging (MTI), strengthen the hypothesis that disturbed
integrity of white matter structures is present in patients
suffering from schizophrenic psychosis (Kubicki et al., 2005,
2007; Ashtari et al., 2007). Therefore, differences in the superior
temporal gyrus (STG) are of special interest, as these structures
include Heschl’s gyrus and planum temporale. Disturbances
in these structures and the inferior longitudinal fasciculus
connecting Broca’s and Wernicke’s area may account for the
pathophysiology of hearing voices (Dierks et al., 1999; Ashtari
et al., 2007).
Alterations of the cingulum bundle have been consistently
reported in previous studies investigating white matter
abnormalities in schizophrenia (Sigmundsson et al., 2001;
Kubicki et al., 2003, 2005; Shergill et al., 2007; Peters et al., 2008).
As the cingulum bundle connects limbic structures—and is
also known to interconnect the thalamus, prefrontal, parietal,
and temporal lobes with the cingulate gyrus—local pathology
of these structures already detectable in first episode patients
might contribute to the hypothesis of dysconnection of the
hippocampal/temporolimbic complex with the dorsolateral
prefrontal cortex (Lipska and Weinberger, 2002; Mori et al.,
2005).
While there was a joint finding in the posterior cingulum
bundle of both patient groups, the striking result of our analysis
was significant differences between both patient groups. These
are localized in the right superior temporal gyrus (superior and
inferior longitudinal fasciculus), right middle temporal lobe, in
the postcentral region, and in a large region of the right fronto-
temporal white matter that corresponds to the right superior
longitudinal fasciculus. In all of these regions, first episode
patients had a negative correlation of S100B concentration to
white matter values while recurrent episode patients had a
positive correlation (Figure 4).
There is a significant body of evidence for disturbed white
matter configuration in temporal regions, including the STG,
the insula (Ashtari et al., 2007; Mitelman et al., 2007; Shergill
et al., 2007; Ellison-Wright and Bullmore, 2009), and the
fronto-temporal white matter structures including the superior
longitudinal fasciculus (Kubicki et al., 2005; Samartzis et al.,
2014). A progression of structural temporal changes has been
reported (Kasai et al., 2003a,b; Ellison-Wright et al., 2008) while
another follow-up study did not find significant progression of
structural changes in temporal regions (DeLisi and Hoff, 2005).
Although based on a cross-sectional analysis, our results
suggest differences in the structural abnormalities of these
regions between schizophrenic patients of earlier (FEP) and later
(REP) stages in terms of a diverging correlation with S100B
concentrations.
Summary and Conclusions
There were significantly different correlations between S100B
concentration and local white matter formations between
both patient groups and healthy controls, as well as between
first episode and recurrent episode patients. Structural white
matter changes showing a different correlation with S100B
between groups are located in brain regions that have been
previously described extensively in the literature to be affected
in schizophrenic patients. Also, these structures are integral parts
in hypotheses about the physical foundation of neurocognitive
symptoms in schizophrenia. A divergent association of S100B
concentration with white matter structural changes could already
be detected in the very early stage of the disorder (FEP). While
there was a finding in the cingulum bundle that appears to
be stable during the course of the disease, the correlation of
S100B concentrations with white matter structural changes was
found to be reversed between patient groups at different stages of
disorder, especially in the white matter of the superior temporal
gyrus corresponding to the inferior longitudinal fasciculus and
fronto-temporal white matter corresponding to the superior
longitudinal fasciculus.
We conclude that S100B is involved in an ongoing dynamic
process associated with local structural changes in white brain
matter of schizophrenic patients. Still, the question is open
whether frequently found increased S100B serum concentration
in psychotic patients at different stages of disorder is a secondary
attempt of protection against an ongoing harmful process or
if pathologically elevated S100B levels themselves can be held
responsible for structural brain damage, either directly or as part
of a biochemical network (Hanson and Gottesman, 2005; Monji
et al., 2009).
Considering the range of measured S100B concentrations
(Table 2), massive glial or neuronal destruction is unlikely to be
the cause of S100B increase in schizophrenia (Rothermundt et al.,
2004a).
A recent study by Streitbuerger et al. (2012) investigated the
correlation between serum S100B levels and gray matter and
white matter parameters with MRI (T1-weighted and diffusion
tensor imaging) in healthy subjects. Here, S100B was specifically
related to the diffusion tensor imaging parameters fractional
anisotropy and radial diffusivity, the latest an indicator of myelin
changes, in the corpus callosum, anterior forceps, and superior
longitudinal fasciculus in female subjects. In contrast, there
was no association between gray matter T1 data and S100B.
Histological data confirmed a co-localization of S100B with
oligodendrocyte markers in the human corpus callosum in this
study. The authors showed additionally, that S100B was most
abundantly expressed in the corpus callosum according to the
whole genome Allen Human Brain Atlas. Based on these data,
one might conclude that serum S100B represents a biomarker
for white matter tracts and, consequently, oligodendroglia,
which might have led to the association between white matter
parameters and schizophrenia in our study, without relevant
effects on gray matter.
Given the fact that S100B is involved in many different
regulation processes and also linked to glutamatergic and
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cytokine systems (Ahlemeyer et al., 2000; Tramontina et al., 2006;
Müller and Schwarz, 2007; Gonçalves et al., 2008), elevated S100B
in schizophrenic psychosis could be an expression of other cross-
linked and ongoing biochemical pathophysiological processes.
Thus, the exact relation of S100B with structural changes remains
open. On the other hand, S100B is a protein that exerts paracrine
and autocrine effects on neurons and glia, and thus plays an
important role in cell proliferation and differentiation, cellular
energy metabolism, and cytoskeletal modification (Rothermundt
et al., 2004a; Gonçalves et al., 2008). Hence, S100B might also be
directly involved in processes leading to structural white matter
changes in schizophrenia.
Limitations of the Study
We included patients at different stages of the disorder to cover
the entire course of the disease in a cross-sectional design. Cross-
sectional studies have their limitations in the interpretation of the
results when discussing questions about progression of structural
changes. The sample sizes used in this study are considered to
be moderate (Honea et al., 2005). However, an essential aspect
of this study was to investigate unmedicated patients and also
to compare first episode patients with patients at a later stage of
the disease. Thus, the sample size was limited due to the small
number of patients fulfilling these criteria.
All patients participating in this study were either neuroleptic-
naïve or unmedicated. Due to practical and ethical reasons, of
those who were unmedicated, some patients were off medication
only for 4 respective 5 days, and some individuals had received
haloperidole as previous medication. Considering the effects of
antipsychotic medication on brain structure (Lieberman et al.,
2005), it would have been desirable to have had a longer
medication-free period before obtaining MRI data, so we cannot
completely rule out a possible effect of medication on the results,
especially in the REP group.
Patient groups differed in mean age. To ensure that found
differences between these groups were not predominantly caused
by effects of age, we included age as nuisance variable in all
analyses. By this method a possible influence of age on the results
can be diminished but not completely be ruled out.
A correlation (r = 0.538, p < 0.001) between S100B
and body mass index (BMI) has been reported in healthy
controls (Steiner et al., 2010a), though such correlation was
not found in patients suffering from schizophrenia (Steiner
et al., 2010b). However, S100B might have other sources than
the brain, e.g., adipose tissue (Gonçalves et al., 2010) and
it is recommendable to consider body mass index in future
studies.
There was also an imbalance in the gender ratio. Differences
in brain structure between men and women are at least in
part a matter of overall size. While such size and shape
differences are controlled by normalizing each image to the
ICBM template (see Section Acquisition of Structural Data
and Image Processing), a possible influence of gender on our
results cannot completely be ruled out. Also, gender specific
correlations between serum S100B and white matter parameters
have been found in a previous study (Streitbuerger et al.,
2012). Hence, we re-performed analyses with a reduced sample
including female subjects only (data not shown). Although this
lead to a considerable reduction of sample size, main effects
were comparable (findings in cingulum bundle, temporal lobe
findings).
For the statistical analysis, a stringent threshold of p =
0.001 was chosen to exclude false positives resulting from
unaccounted confounding variables (Ashburner and Friston,
2000). Furthermore, having exclusively found significant changes
in anatomical structures previously described to be altered
in schizophrenia in a non-region-of-interest-approach, it is
reasonable to assume that our results are valid.
We used VBM to find local differences in white matter values
of T1 weighted MR images and assigned detected clusters to
anatomical fiber structures according to an atlas of human brain
white matter, presuming that localizations of clusters found in
our analysis correspond to these structures. This method cannot
show the fiber tracts themselves, including their directions and
disruptions. To prove that these fiber tracts are indeed disrupted
and that the disruptions are associated with S100B, future
studies in this field should also utilize techniques such as DTI
or MTI.
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